ObsEva (OBSV) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period ObsEva (NASDAQ:OBSV) Now Covered by StockNews.comJanuary 18 at 2:13 AM | americanbankingnews.comStockNews.com Begins Coverage on ObsEva (NASDAQ:OBSV)January 12, 2025 | americanbankingnews.comObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 26, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comObsEva SA OBSEFNovember 11, 2023 | morningstar.comObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comObsEva Files Year End 2022 Financial StatementsMarch 31, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 15, 2023 | finance.yahoo.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | markets.businessinsider.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 13, 2023 | finance.yahoo.comWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionMarch 3, 2023 | benzinga.comWhy Is ObsEva (OBSV) Stock Up 93% Today?March 3, 2023 | investorplace.comWhy ObsEva (OBSV) Stock Is Down 36% TodayFebruary 24, 2023 | investorplace.comObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandFebruary 24, 2023 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingJanuary 12, 2023 | uk.finance.yahoo.comObsEva Announces Dismissal of Moratorium ProceedingsDecember 19, 2022 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 14, 2022 | finance.yahoo.comObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue EstimatesDecember 1, 2022 | finance.yahoo.comObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateDecember 1, 2022 | finance.yahoo.comObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsOctober 27, 2022 | finance.yahoo.comObsEva SA (OBSV)October 16, 2022 | finance.yahoo.comObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of NolasibanOctober 14, 2022 | markets.businessinsider.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.comOctober 13, 2022 | marketscreener.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - BenzingaOctober 13, 2022 | benzinga.comObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.comOctober 13, 2022 | marketscreener.comObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswireOctober 13, 2022 | globenewswire.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in ChinaOctober 13, 2022 | finance.yahoo.comOBSV.PH - Obseva SA | Stock Price & Latest News | ReutersOctober 6, 2022 | reuters.comObsEva Flat on Restructuring Initiatives - Baystreet.caSeptember 15, 2022 | baystreet.caAfter FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its StaffSeptember 13, 2022 | finance.yahoo.comObsEva Announces Progress on Restructuring Initiatives - GlobeNewswireSeptember 13, 2022 | globenewswire.comOBSV.O - Obseva SA | Stock Price & Latest News | ReutersSeptember 11, 2022 | reuters.comOBSV.N - Obseva SA | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comThis Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'September 7, 2022 | finance.yahoo.comHot Penny Stocks For Your Buy List in September? 3 to Watch - StreetInsider.comAugust 31, 2022 | streetinsider.comBluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know By Benzinga - Investing.com UKAugust 31, 2022 | uk.investing.comGlobal Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com - Business WireAugust 25, 2022 | businesswire.comObsEva stock dips on Nasdaq non-compliance notice - Seeking AlphaAugust 23, 2022 | seekingalpha.comObsEva Receives Nasdaq Non-Compliance Notice - GlobeNewswireAugust 22, 2022 | globenewswire.comObsEva Receives Nasdaq Non-Compliance NoticeAugust 22, 2022 | finance.yahoo.comOBSEVA : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K - Marketscreener.comAugust 19, 2022 | marketscreener.comObsEva: Q2 Earnings Insights - BenzingaAugust 18, 2022 | benzinga.comObsEva Files Second Quarter 2022 Financial Statements - GlobeNewswireAugust 17, 2022 | globenewswire.comObsEva Files Second Quarter 2022 Financial StatementsAugust 17, 2022 | finance.yahoo.comKissei Pharmaceutical : Supplementary Explanatory Materials on Financial Results for the Three Months ended June 30, 2022 - Marketscreener.comAugust 5, 2022 | marketscreener.comAll You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy - NasdaqAugust 3, 2022 | nasdaq.com Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address OBSV Media Mentions By Week OBSV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OBSV News Sentiment▼0.000.57▲Average Medical News Sentiment OBSV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OBSV Articles This Week▼10▲OBSV Articles Average Week Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Lisata Therapeutics News Cadrenal Therapeutics News Verrica Pharmaceuticals News Chemomab Therapeutics News Omega Therapeutics News Marinus Pharmaceuticals News CEL-SCI News Sol-Gel Technologies News Unity Biotechnology News Daré Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OBSV) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.